Mankind Pharma (MANKIND) Q3 24/25 earnings summary

Executive summary

• Q3 and 9M FY25 marked a transformative period with the acquisition and integration of BSV, expanding into high-entry barrier and specialty R&D platforms.

• Market share in IPM increased by 40 bps to 4.8% in Dec 2024, up from 4.4% in March, driven by BSV acquisition.

• Four growth engines: steady base business, specialty chronic, high-potential OTC, and BSV's super specialty portfolio.

• Approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024.

• Completed acquisition of Bharat Serums and Vaccines Limited (BSV) for INR 13,768 crores on October 23, 2024.

Financial highlights

• Q3 FY25 consolidated revenue at INR 3,230 crore, up 24% YoY; 9M FY25 consolidated revenue at INR 9,200 crore, up 16.5%.

• Q3 FY25 EBITDA at INR 833 crore (adjusted margin 27.7%), up 36.4% YoY.

• Q3 FY25 PAT at INR 385 crore, down 16.4% YoY due to higher finance and amortization costs from acquisitions.

• Gross margin improved to 71% in Q3 FY25 from 68.3% YoY.

• Basic EPS (consolidated) for Q3 FY25: INR 9.45.

Outlook and guidance

• BSV expected to deliver 15%+ growth with margins starting at 26-28%, aiming for 30% in 2-3 years.

• Synergy benefits from BSV integration estimated at INR 50-100 crore over 12-24 months.

• Focus on expanding chronic and super specialty segments, leveraging BSV acquisition, and growing consumer healthcare.

• Proceeds from QIP and NCD/CP issues are earmarked for debt repayment and future investments.

• Corrective actions in field force and leadership expected to be completed within Q4 FY25, setting up for stronger growth ahead.